{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:27:41Z","timestamp":1792794461272,"version":"4.5.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"8","funder":[{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs","doi-asserted-by":"publisher","award":["5I01CX001379"],"award-info":[{"award-number":["5I01CX001379"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CSR&D Research Career Development Transition Award","award":["5IK4CX002091"],"award-info":[{"award-number":["5IK4CX002091"]}],"id":[{"id":"https:\/\/ror.org\/02xjhr934","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>The comorbidity of major depressive disorder (MDD) and alcohol use disorder (AUD) is often treated inadequately. This study evaluated the impact of adding the opioid receptor blocker, naltrexone, to the NMDA glutamate receptor antagonist, ketamine, for the treatment of MDD comorbid with AUD. In so doing, it also attempted to shed light on the contribution of opioid receptor stimulation to the antidepressant effects of ketamine in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy of ketamine plus naltrexone to ketamine plus saline and midazolam plus saline for reducing depression and decreasing alcohol consumption in outpatients with comorbid MDD and AUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>A 3-arm, randomized, double-blind, parallel-group study was conducted. Participants were 65 adults with current MDD and AUD, with Montgomery\u2013\u00c5sberg Depression Rating Scale (MADRS) total score of 20 or higher and heavy drinking at least 4 times in the month prior to randomization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Randomized (1:1:1) to receive (1) intravenous (IV) ketamine (0.5\u00a0mg\/kg) once a week for 4\u00a0weeks (a total of 4 infusions) plus intramuscular (IM) naltrexone (380\u00a0mg), (2) IV ketamine plus IM saline, or (3) IV midazolam (0.045\u00a0mg\/kg) plus IM saline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Co-primary: MADRS; complete alcohol abstinence. Secondary: alcohol craving, anxiety, quality of life, safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 65 participants, 58 received at least 1 ketamine\/midazolam infusion: 20 in ketamine-naltrexone, 19 in ketamine-saline, 19 in midazolam-saline. All groups improved significantly (&amp;gt;80% depression remission). No group differences were observed in MADRS changes during treatment (primary outcome), although antidepressant effects persisted longer in ketamine groups compared to midazolam. There were no significant group differences in alcohol-related outcomes. Ketamine groups showed greater improvement in anxiety and quality of life (secondary outcomes) than midazolam, with the ketamine-naltrexone group showing greater improvement in anxiety than ketamine-saline. No study-related serious adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This study found similar antidepressant and anti-alcohol effects across 3 groups. Compared to midazolam, the ketamine groups showed longer-lasting antidepressant effects and greater improvements in anxiety and quality of life. Comparable outcomes between the 2 ketamine groups suggest opioid receptor antagonism did not alter ketamine\u2019s therapeutic effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>The study was registered at ClinicalTrials.gov (Identifier: NCT02461927).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijnp\/pyaf056","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T12:10:07Z","timestamp":1754655007000},"source":"Crossref","is-referenced-by-count":16,"title":["Antidepressant efficacy of ketamine plus naltrexone for major depression comorbid with alcohol use disorder: a randomized controlled trial"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7983-9957","authenticated-orcid":false,"given":"Gihyun","family":"Yoon","sequence":"first","affiliation":[{"name":"Department of Psychiatry, VA Connecticut Healthcare System , West Haven, CT ,","place":["United States"]},{"name":"Department of Psychiatry, Yale University School of Medicine , New Haven, CT ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Pittman","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine , New Haven, CT ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Ralevski","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, VA Connecticut Healthcare System , West Haven, CT ,","place":["United States"]},{"name":"Department of Psychiatry, Yale University School of Medicine , New Haven, CT ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismene L","family":"Petrakis","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, VA Connecticut Healthcare System , West Haven, CT ,","place":["United States"]},{"name":"Department of Psychiatry, Yale University School of Medicine , New Haven, CT ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H","family":"Krystal","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, VA Connecticut Healthcare System , West Haven, CT ,","place":["United States"]},{"name":"Department of Psychiatry, Yale University School of Medicine , New Haven, CT ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"2026031303420696900_ref1","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","article-title":"Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the global burden of disease study 2016","volume":"392","author":"Griswold","year":"2018","journal-title":"Lancet"},{"key":"2026031303420696900_ref2","doi-asserted-by":"crossref","first-page":"e1001547","DOI":"10.1371\/journal.pmed.1001547","article-title":"Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010","volume":"10","author":"Ferrari","year":"2013","journal-title":"PLoS Med"},{"key":"2026031303420696900_ref3","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","article-title":"Comorbidity of mental disorders with alcohol and other drug abuse. Results from the epidemiologic catchment area (ECA) study","volume":"264","author":"Regier","year":"1990","journal-title":"JAMA"},{"key":"2026031303420696900_ref4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/archpsyc.1997.01830160031005","article-title":"Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey","volume":"54","author":"Kessler","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"2026031303420696900_ref5","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/archpsyc.1987.01800180015002","article-title":"Psychopathology as a predictor of treatment outcome in alcoholics","volume":"44","author":"Rounsaville","year":"1987","journal-title":"Arch Gen Psychiatry"},{"key":"2026031303420696900_ref6","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.291.15.1887","article-title":"Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis","volume":"291","author":"Nunes","year":"2004","journal-title":"JAMA"},{"key":"2026031303420696900_ref7","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.comppsych.2013.10.007","article-title":"Comorbidity between major depression and alcohol use disorder from adolescence to adulthood","volume":"55","author":"Briere","year":"2014","journal-title":"Compr Psychiatry"},{"key":"2026031303420696900_ref8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/ajad.12219","article-title":"Correlates of major depressive disorder with and without comorbid alcohol use disorder nationally in the veterans health administration","volume":"24","author":"Yoon","year":"2015","journal-title":"Am J Addict"},{"key":"2026031303420696900_ref9","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s40429-018-0213-z","article-title":"Pharmacological and psychological treatments for comorbid alcohol use disorder and depressive disorder: a review","volume":"5","author":"Yoon","year":"2018","journal-title":"Curr Addict Rep"},{"key":"2026031303420696900_ref10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am J Psychiatry"},{"key":"2026031303420696900_ref11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/ph3010019","article-title":"The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments","volume":"3","author":"Machado-Vieira","year":"2010","journal-title":"Pharmaceuticals"},{"key":"2026031303420696900_ref12","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","article-title":"Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression","volume":"172","author":"Newport","year":"2015","journal-title":"Am J Psychiatry"},{"key":"2026031303420696900_ref13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1017\/s0033291714001603","article-title":"A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes","volume":"45","author":"McGirr","year":"2015","journal-title":"Psychol Med"},{"key":"2026031303420696900_ref14","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1007\/s00213-014-3664-5","article-title":"Ketamine administration in depressive disorders: a systematic review and meta-analysis","volume":"231","author":"Fond","year":"2014","journal-title":"Psychopharmacology"},{"key":"2026031303420696900_ref15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1176\/appi.ajp.2019.19070684","article-title":"A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial","volume":"177","author":"Dakwar","year":"2020","journal-title":"Am J Psychiatry"},{"key":"2026031303420696900_ref16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2021.21030277","article-title":"Adjunctive ketamine with relapse prevention\u2013based psychological therapy in the treatment of alcohol use disorder","volume":"179","author":"Grabski","year":"2022","journal-title":"Am J Psychiatry"},{"key":"2026031303420696900_ref17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0376-8716(95)01160-4","article-title":"Comorbidity between DSM-IV alcohol use disorders and major depression: results of a national survey","volume":"39","author":"Grant","year":"1995","journal-title":"Drug Alcohol Depend"},{"key":"2026031303420696900_ref18","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism","volume":"175","author":"Williams","year":"2018","journal-title":"Am J Psychiatry"},{"key":"2026031303420696900_ref19","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1176\/appi.ajp.2018.18070800","article-title":"Is there really nothing new under the sun? Is low-dose ketamine a fast-acting antidepressant simply because it is an opioid?","volume":"175","author":"George","year":"2018","journal-title":"Am J Psychiatry"},{"key":"2026031303420696900_ref20","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1073\/pnas.1916570117","article-title":"Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents","volume":"117","author":"Klein","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026031303420696900_ref21","doi-asserted-by":"crossref","first-page":"173228","DOI":"10.1016\/j.pbb.2021.173228","article-title":"Opioid receptor system contributes to the acute and sustained antidepressant-like effects, but not the hyperactivity motor effects of ketamine in mice","volume":"208","author":"Zhang","year":"2021","journal-title":"Pharmacol Biochem Behav"},{"key":"2026031303420696900_ref22","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.biopsych.2022.12.019","article-title":"Mu opioid receptor activation mediates (S)-ketamine reinforcement in rats: implications for abuse liability","volume":"93","author":"Levinstein","year":"2023","journal-title":"Biol Psychiatry"},{"key":"2026031303420696900_ref23","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.biopsych.2018.11.006","article-title":"Lack of opioid system in the antidepressant actions of ketamine","volume":"85","author":"Zhang","year":"2019","journal-title":"Biol Psychiatry"},{"key":"2026031303420696900_ref24","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/JCP.0000000000001237","article-title":"Opioid receptor \u03bc-1 and ketamine effects in a suicidal depression trial: a post hoc exploration","volume":"40","author":"Grunebaum","year":"2020","journal-title":"J Clin Psychopharmacol"},{"key":"2026031303420696900_ref25","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/ijnp\/pyaa030","article-title":"Effects of mu-opiate receptor gene polymorphism rs1799971 (A118G) on the antidepressant and dissociation responses in esketamine nasal spray clinical trials","volume":"23","author":"Saad","year":"2020","journal-title":"Int J Neuropsychopharmacol"},{"key":"2026031303420696900_ref26","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/j.biopsych.2019.02.008","article-title":"Concurrent use of buprenorphine, methadone, or naltrexone does not inhibit ketamine\u2019s antidepressant activity","volume":"85","author":"Marton","year":"2019","journal-title":"Biol Psychiatry"},{"key":"2026031303420696900_ref27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamapsychiatry.2018.3990","article-title":"Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder","volume":"76","author":"Yoon","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"2026031303420696900_ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.0763","article-title":"Rigorous trial design is essential to understand the role of opioid receptors in ketamine\u2019s antidepressant effect-reply","volume":"76","author":"Krystal","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"2026031303420696900_ref29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jamapsychiatry.2019.0766","article-title":"Rigorous trial design is essential to understand the role of opioid receptors in ketamine\u2019s antidepressant effect","volume":"76","author":"Heifets","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"2026031303420696900_ref30","doi-asserted-by":"crossref","first-page":"11200","DOI":"10.1073\/pnas.2001264117","article-title":"Are NMDA and opioid receptors involved in the antidepressant actions of ketamine?","volume":"117","author":"Hashimoto","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026031303420696900_ref31","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"2026031303420696900_ref32","volume-title":"Vivitrol Package Insert. Silver Spring, MD","author":"FDA"},{"key":"2026031303420696900_ref33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-4612-0357-5_3","volume-title":"Measuring Alcohol Consumption","author":"Sobell","year":"1992"},{"key":"2026031303420696900_ref34","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","article-title":"The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression","volume":"54","author":"Rush","year":"2003","journal-title":"Biol Psychiatry"},{"key":"2026031303420696900_ref35","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.drugalcdep.2015.06.040","article-title":"The Yale Craving Scale: development and psychometric properties","volume":"154","author":"Rojewski","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"2026031303420696900_ref36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br J Med Psychol"},{"key":"2026031303420696900_ref37","first-page":"321","article-title":"Quality of life enjoyment and satisfaction questionnaire: a new measure","volume":"29","author":"Endicott","year":"1993","journal-title":"Psychopharmacol Bull"},{"key":"2026031303420696900_ref38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/01.chi.0000198590.38325.81","article-title":"Pediatric quality of life enjoyment and satisfaction questionnaire (PQ-LES-Q): reliability and validity","volume":"45","author":"Endicott","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2026031303420696900_ref39","volume-title":"Structured Clinical Interview for DSM-5 Disorders\u2013Research Version (SCID-5-RV)","author":"First","year":"2014"},{"key":"2026031303420696900_ref40","first-page":"343","article-title":"SAFTEE: a technique for the systematic assessment of side effects in clinical trials","volume":"22","author":"Levine","year":"1986","journal-title":"Psychopharmacol Bull"},{"key":"2026031303420696900_ref41","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"2026031303420696900_ref42","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"2026031303420696900_ref43","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pscychresns.2010.10.009","article-title":"The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS","volume":"191","author":"Valentine","year":"2011","journal-title":"Psychiatry Res Neuroimaging"},{"key":"2026031303420696900_ref44","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1111\/bcp.15374","article-title":"Ketamine treatment for refractory anxiety: a systematic review","volume":"88","author":"Tully","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2026031303420696900_ref45","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/0269881118762073","article-title":"Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders","volume":"32","author":"Glue","year":"2018","journal-title":"J Psychopharmacol"},{"key":"2026031303420696900_ref46","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/npp.2017.194","article-title":"Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial","volume":"43","author":"Taylor","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"2026031303420696900_ref47","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1530-0277.2007.00344.x","article-title":"Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam","volume":"31","author":"Krupitsky","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"key":"2026031303420696900_ref48","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am J Psychiatry"},{"key":"2026031303420696900_ref49","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102127","article-title":"Ketamine for the treatment of major depression: a systematic review and meta-analysis","volume":"62","author":"Nikolin","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026031303420696900_ref50","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40265-015-0358-1","article-title":"Identification and management of alcohol withdrawal syndrome","volume":"75","author":"Mirijello","year":"2015","journal-title":"Drugs"},{"key":"2026031303420696900_ref51","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3390\/ph17040473","article-title":"Pharmacokinetics, pharmacodynamics, and side effects of midazolam: a review and case example","volume":"17","author":"Peter","year":"2024","journal-title":"Pharmaceuticals"},{"key":"2026031303420696900_ref52","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression","volume":"74","author":"Murrough","year":"2013","journal-title":"Biol Psychiatry"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaf056\/64004133\/pyaf056.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/8\/pyaf056\/64004133\/pyaf056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/8\/pyaf056\/64004133\/pyaf056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:42:18Z","timestamp":1773387738000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyaf056\/8230270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyaf056","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,8,1]]},"article-number":"pyaf056"}}